UPSTREAM BIO, INC. Revenue
UPSTREAM BIO, INC. (UPB) reported Revenue of $773.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-11
- UPSTREAM BIO, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $773.00K, a 17.50% decline year-over-year.
- UPSTREAM BIO, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-03-31 was $1.03M, a 82.69% increase year-over-year.
- UPSTREAM BIO, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $668.00K, a 8.97% increase year-over-year.
- UPSTREAM BIO, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $683.00K, a 12.52% increase year-over-year.
- UPSTREAM BIO, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $2.85M, a 20.42% increase from fiscal 2024.
- UPSTREAM BIO, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $2.37M, a 0.42% decline from fiscal 2023.
- UPSTREAM BIO, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $2.38M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $773.00K 10-Q · filed 2026-08-11 | $1.81M 10-Q · filed 2026-08-11 | $2.48M derived: sum of 3 quarters · filed 2026-08-11 | $3.16M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $1.03M 10-Q · filed 2026-05-13 | $1.70M derived: sum of 2 quarters · filed 2026-05-13 | $2.38M derived: sum of 3 quarters · filed 2026-05-13 | $3.32M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $668.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $1.35M derived: sum of 2 quarters · filed 2026-03-26 | $2.29M derived: sum of 3 quarters · filed 2026-08-11 | $2.85M 10-K · filed 2026-03-26 |
| 2025-09-30 | $683.00K 10-Q · filed 2025-11-05 | $1.62M derived: sum of 2 quarters · filed 2026-08-11 | $2.19M 10-Q · filed 2025-11-05 | $2.80M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $937.00K 10-Q · filed 2026-08-11 | $1.50M 10-Q · filed 2026-08-11 | $2.12M derived: sum of 3 quarters · filed 2026-08-11 | $2.72M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $566.00K 10-Q · filed 2026-05-13 | $1.18M derived: sum of 2 quarters · filed 2026-05-13 | $1.79M derived: sum of 3 quarters · filed 2026-05-13 | $2.30M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $613.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $1.22M derived: sum of 2 quarters · filed 2026-03-26 | $1.73M derived: sum of 3 quarters · filed 2026-03-26 | $2.37M 10-K · filed 2026-03-26 |
| 2024-09-30 | $607.00K 10-Q · filed 2025-11-05 | $1.12M derived: sum of 2 quarters · filed 2025-11-05 | $1.76M 10-Q · filed 2025-11-05 | $2.21M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $510.00K 10-Q · filed 2025-08-06 | $1.15M 10-Q · filed 2025-08-06 | $1.60M derived: sum of 3 quarters · filed 2025-08-06 | $2.22M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $640.00K 10-Q · filed 2025-05-06 | $1.09M derived: sum of 2 quarters · filed 2025-05-06 | $1.71M derived: sum of 3 quarters · filed 2025-05-06 | |
| 2023-12-31 | $450.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | $1.07M derived: sum of 2 quarters · filed 2025-03-12 | $2.38M 10-K · filed 2025-03-12 | |
| 2023-09-30 | $621.00K 10-Q · filed 2024-11-07 | $1.93M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |